FierceBiotech 23 mar 2026 Pfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval push
FierceBiotech 20 mar 2026 Genentech antibody fails to boost muscle in rare diseases, raising questions for obesity trial
FierceBiotech 20 mar 2026 Gilead turns down chance to build on Assembly's phase 1-stage HBV antiviral
FierceBiotech 20 mar 2026 Novartis pays Synnovation $2B upfront for breast cancer program as rivals circle
FierceBiotech 20 mar 2026 Embecta to buy auto-injector maker Owen Mumford for $200M to diversify beyond insulin
FierceBiotech 19 mar 2026 Lilly's obesity discovery partner Fauna sees weight loss potential in hibernating mammals
FierceBiotech 19 mar 2026 AstraZeneca to build cell therapy manufacturing hub, R&D center in Shanghai
FierceBiotech 19 mar 2026 Phage-focused BiomX resets after adverse events derail pipeline, considers pivot to defense sector
FierceBiotech 19 mar 2026 Syneos Health scoops up Chinese CRO to secure place in ‘rapidly growing market’
FierceBiotech 19 mar 2026 Lilly's triple-G bet lowers blood sugar, prompts 16.8% weight loss in phase 3 diabetes trial
FierceBiotech 19 mar 2026 Rare disease advocates stage 'funeral' at FDA, demand 4 actions of agency and Congress